ADMA BIOLOGICS, INC. Interest Expense Nonoperating
ADMA BIOLOGICS, INC. (ADMA) reported Interest Expense Nonoperating of $3.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- ADMA BIOLOGICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $3.42M, a 86.70% increase year-over-year.
- ADMA BIOLOGICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $2.10M, a 6.33% increase year-over-year.
- ADMA BIOLOGICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $1.63M, a 43.52% decline year-over-year.
- ADMA BIOLOGICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $1.68M, a 52.13% decline year-over-year.
- ADMA BIOLOGICS, INC. interest expense nonoperating for fiscal 2025 was $7.11M, a 48.96% decline from fiscal 2024.
- ADMA BIOLOGICS, INC. interest expense nonoperating for fiscal 2024 was $13.93M, a 44.34% decline from fiscal 2023.
- ADMA BIOLOGICS, INC. interest expense nonoperating for fiscal 2023 was $25.03M, a 29.81% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. interest expense nonoperating for fiscal 2022 was $19.28M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.42M 10-Q · filed 2026-08-05 | $5.52M 10-Q · filed 2026-08-05 | $7.15M derived: sum of 3 quarters · filed 2026-08-05 | $8.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-06 | $3.73M derived: sum of 2 quarters · filed 2026-05-06 | $5.40M derived: sum of 3 quarters · filed 2026-05-06 | $7.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.30M derived: sum of 2 quarters · filed 2026-02-25 | $5.13M derived: sum of 3 quarters · filed 2026-08-05 | $7.11M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.68M 10-Q · filed 2025-11-05 | $3.51M derived: sum of 2 quarters · filed 2026-08-05 | $5.48M 10-Q · filed 2025-11-05 | $8.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-05 | $3.81M 10-Q · filed 2026-08-05 | $6.69M derived: sum of 3 quarters · filed 2026-08-05 | $10.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.98M 10-Q · filed 2026-05-06 | $4.85M derived: sum of 2 quarters · filed 2026-05-06 | $8.35M derived: sum of 3 quarters · filed 2026-05-06 | $12.14M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.38M derived: sum of 2 quarters · filed 2026-02-25 | $10.16M derived: sum of 3 quarters · filed 2026-02-25 | $13.93M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.50M 10-Q · filed 2025-11-05 | $7.28M derived: sum of 2 quarters · filed 2025-11-05 | $11.05M 10-Q · filed 2025-11-05 | $17.27M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.78M 10-Q · filed 2025-08-06 | $7.55M 10-Q · filed 2025-08-06 | $13.77M derived: sum of 3 quarters · filed 2026-02-25 | $20.16M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.77M 10-Q · filed 2025-05-07 | $9.98M derived: sum of 2 quarters · filed 2026-02-25 | $16.38M derived: sum of 3 quarters · filed 2026-02-25 | $22.68M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.61M derived: sum of 2 quarters · filed 2026-02-25 | $18.91M derived: sum of 3 quarters · filed 2026-02-25 | $25.03M 10-K · filed 2026-02-25 |
| 2023-09-30 | $6.40M 10-Q · filed 2024-11-07 | $12.70M derived: sum of 2 quarters · filed 2024-11-07 | $18.81M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $6.30M 10-Q · filed 2024-08-08 | $12.41M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $19.28M 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |